#London #United Kingdom #Immuno-Oncology #HanchorBio #HCB101

HanchorBio's HCB101 Makes Waves at ESMO Immuno-Oncology Congress 2025

In an exciting development within the biotechnology landscape, HanchorBio Inc. has announced an important milestone for its flagship treatment, HCB101. The company has been selected to present new clinical data at the highly esteemed ESMO Immuno-Oncology Congress 2025, set to take place in London. This marks a significant achievement for HanchorBio, as it is the first time they will showcase clinical data through an oral presentation at an international oncology conference. The presentation will emphasize the potential of HCB101 as a next-generation immunotherapy, geared towards treating challenging cancers such as gastric cancer and triple-negative breast cancer.

Key Insights into HCB101

HCB101 is distinguished as a macrophage-checkpoint therapy that has shown promising results in early clinical trials. The data presented at ESMO-IO highlights a clean safety profile and favorable early antitumor activity across various solid tumors and lymphomas. This development underscores the therapeutic potential of HCB101, particularly in treating what are considered 'cold' tumors, which have traditionally responded poorly to existing therapies.

Presentation Details

The mini-oral presentation will take place on December 11, 2025, with Dr. Fangling Ning from the Affiliated Hospital of Binzhou Medical University as the first author. The abstract titled HCB101, a Differentiated SIRPα Fusion Protein, Demonstrates Favorable Safety and Early Antitumor Activity Across Solid Tumors and Lymphoma will be showcased by Alvin Luk, PhD, the President and Chief Medical Officer of HanchorBio.

During the presentation, key data will be shared, demonstrating that HCB101 has achieved remarkable tumor regression rates, with head and neck squamous cell carcinoma (HNSCC) showing about a 42% reduction in tumor size that persists for over 32 weeks. Moreover, marginal zone lymphoma (MZL) displayed an impressive 89% tumor regression rate that also extended beyond 16 weeks.

Addressing Challenges in Cancer Therapy

Since the inception of CD47 therapies, a significant hurdle has been the challenge of balancing safety and effectiveness in the treatment of challenging tumors. According to Scott Liu, PhD, Founder and CEO of HanchorBio, the breakthrough achieved with HCB101 results from a novel design that utilizes AI-guided structural modeling to enhance the interaction between SIRPα and CD47. This innovative approach has addressed previous efficacy issues while ensuring minimal side effects for patients.

HCB101's Broad Applicability

HCB101's innovative design allows it to target tumor CD47 while sparing red blood cells, thus significantly reducing the common side effects associated with anti-CD47 therapies, such as anemia and thrombocytopenia. The therapy’s strong macrophage activation and broad antitumor activity across various preclinical models further position HCB101 as a potential cornerstone treatment in immuno-oncology, much like PD-1/PD-L1 inhibitors have become in recent years.

Commitment to Transformative Medicines

HanchorBio envisions protecting patient outcomes while continually improving therapeutic efficacy. As they progress, their efforts are structured around expanding HCB101’s use from second-line to first-line therapies, aiming to stay ahead of patient needs in oncology treatment paradigms. With an impressive clean safety profile and promising early data, HCB101 is on its way to being potentially transformative in the treatment of solid tumors.

Conclusion

As HanchorBio prepares to present at the ESMO Immuno-Oncology Congress 2025, the spotlight will be on its revolutionary approach to cancer therapy with HCB101. The recognition of their work within the scientific community highlights the growing importance of innovative immunotherapies in the ongoing fight against various forms of cancer. HanchorBio aims not only to push the boundaries of cancer treatment options but to redefine them altogether, ensuring that the future of oncology is filled with hope and robust treatment options. For more information, visit HanchorBio's official website.